Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine

Phase 1 Terminated 49 enrolled Matthias Schwab

RandomizedSingle-groupOpen-labelBasic science

Summary

Pharmacokinetic of Metoclopramide (MCP) in correlation to polymorphisms of CYP2D6 and Dopamine-D2-Receptor. Pharmacokinetic of Diphenhydramine (DPH) in correlation to polymorphisms of CYP2D6

Timeline

Start: 2009-07
Primary completion: 2015-06
Completion: 2015-06

Publications

Background Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta. 2007 Mar;1770(3):489-94. doi: 10.1016/j.bbagen.2006.09.019. Epub 2006 Oct 4.
Background Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007 Nov 20;25(33):5187-93. doi: 10.1200/JCO.2007.12.2705.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Diphenhydramine	Unknown	50 mg	Oral
Comparator	Metoclopramide	Small molecule	10 mg	Intravenous

Indications

No indication recorded.